3 studies found for:    7477169 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
Conditions: Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Ibritumomab Tiuxetan (Zevalin)
2 Terminated Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: MK2206
3 Unknown  The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma
Condition: B-Cell Lymphoma Originating in the CNS
Intervention: Drug: Temozolomide

Indicates status has not been verified in more than two years